BMD is proud to be the exclusive distributor of SERALITE® in the Benelux. Abingdon Health is focusing on haematology oncology and specifically in the area of B-Cell dyscrasias. They developed a rapid test in this market: SERALITE® – FLC, the world’s first rapid device for aiding the diagnosis and monitoring of multiple myeloma patients.
SERALITE® allows the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in Serum or Urine.
2 techniques are available:
Rapid lateral flow (LF)
Compact and light weight allowing to be run in any laboratory setting. Single-use, quantitative, in vitro immunochromatographic competitive assay.
Provides cost effective, robust and accurate measurement of both kappa and lambda free light chains (FLC) in serum